Pearl River Capital’s 10x Genomics TXG Stock Holding History

Pearl River Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-16,712	Closed	-$627K	–	630
2024 Q1	$627K	Buy	+16,712	New	+$734K	0.1%	268
2021 Q4	–	Sell	-4,286	Closed	-$624K	–	572
2021 Q3	$624K	Sell	4,286 -4,360	-50%	-$749K	0.17%	185
2021 Q2	$1.69M	Buy	+8,646	New	+$1.56M	0.47%	58

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Pearl River Capital's TXG Position: Q2 2024 in Review

Pearl River Capital sold out of 10x Genomics (TXG) in Q2 2024, closing a stake of 16,712 shares — an estimated $627K sold.

Pearl River Capital first reported a position in TXG in Q2 2021 and held it in 3 quarters. The position peaked at $1.69M in Q2 2021. 261 funds tracked by Wall St. Rank hold TXG as of Q2 2024.

Pearl River Capital reported no remaining 10x Genomics position as of Q2 2024 after selling out during the quarter.
Pearl River Capital sold 16,712 10x Genomics shares in Q2 2024, an estimated $627K.
Pearl River Capital first reported a position in 10x Genomics in Q2 2021 and held it in 3 quarters.
Pearl River Capital's 10x Genomics position peaked at $1.69M in Q2 2021.
261 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2024.

Based on Pearl River Capital's 13F filing for Q2 2024, filed 13 Aug 2024.